Russell Investments Group Ltd. Lowers Holdings in Alector, Inc. (NASDAQ:ALEC)

Russell Investments Group Ltd. lowered its holdings in shares of Alector, Inc. (NASDAQ:ALEC) by 22.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 56,239 shares of the company’s stock after selling 16,386 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.06% of Alector worth $106,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ALEC. JPMorgan Chase & Co. lifted its position in shares of Alector by 64.7% in the third quarter. JPMorgan Chase & Co. now owns 2,728,823 shares of the company’s stock worth $12,716,000 after buying an additional 1,072,298 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Alector by 8.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,903,942 shares of the company’s stock worth $8,874,000 after acquiring an additional 148,357 shares in the last quarter. Barclays PLC boosted its position in shares of Alector by 132.4% during the 3rd quarter. Barclays PLC now owns 176,800 shares of the company’s stock valued at $824,000 after acquiring an additional 100,731 shares during the last quarter. Los Angeles Capital Management LLC boosted its position in shares of Alector by 61.2% during the 4th quarter. Los Angeles Capital Management LLC now owns 90,736 shares of the company’s stock valued at $171,000 after acquiring an additional 34,450 shares during the last quarter. Finally, Jane Street Group LLC grew its holdings in shares of Alector by 24.2% in the third quarter. Jane Street Group LLC now owns 154,942 shares of the company’s stock valued at $722,000 after purchasing an additional 30,180 shares in the last quarter. Institutional investors own 85.83% of the company’s stock.

Alector Trading Down 3.4 %

Shares of ALEC opened at $1.14 on Friday. The company’s fifty day simple moving average is $1.30 and its 200-day simple moving average is $2.36. The company has a market cap of $112.96 million, a P/E ratio of -0.67 and a beta of 0.73. Alector, Inc. has a twelve month low of $0.87 and a twelve month high of $6.78.

Alector (NASDAQ:ALEC) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.59. Alector had a negative net margin of 257.54% and a negative return on equity of 108.77%. The company had revenue of $54.24 million for the quarter, compared to analyst estimates of $20.41 million. Analysts predict that Alector, Inc. will post -1.88 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on ALEC shares. Morgan Stanley reiterated an “underweight” rating and set a $1.50 price objective (down previously from $3.00) on shares of Alector in a research report on Friday, March 7th. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Alector in a report on Thursday, February 27th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $3.50.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.